Showing results (251-260 of 406) with videos related to
Sort By:
Pageof 41
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.Haematologica|August 28, 2025
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myelomaHanny Musa, Michał Mielnik, Suzanne Trudel, et al.Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.Blood Cancer Journal|March 1, 2020
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myelomaTatjana Bilich, Annika Nelde, Jens Bauer, et al.Cancer Research|May 24, 2018
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell TransformationMarkus W Löffler, Daniel J Kowalewski, Linus Backert, et al.BMC Medical Genetics|August 17, 2018
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implicationsMarkus W Löffler, Julia Steinhilber, Franz J Hilke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemiaFrederik Damm, Michael Heuser, Michael Morgan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemiaFrederik Damm, Tina Oberacker, Felicitas Thol, et al.Blood|March 5, 2011
Integrative prognostic risk score in acute myeloid leukemia with normal karyotypeFrederik Damm, Michael Heuser, Michael Morgan, et al.Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.Pageof 41